Table 3.

Phase III and IV biological agents targeting Th-2 inflammation and relevant suggested biomarkers indicative of a response.

Biological Agent	Target	Route of Administration	Relevant Biomarkers (Response/Predictive)
Omalizumab	IgE	SC	Sputum Eosinophils FeNO IgE
Mepolizumab	IL-5	SC	Blood/Sputum Eosinophils
Reslizumab	Il-5	IV	Blood/Sputum Eosinophils
Benralizumab	IL-5 receptor α	SC	Blood/Sputum Eosinophils EDN
Dupilumab	IL-4 receptor	SC	FeNO
Tezepelumab	thymic stromal lymphopoietin	SC	*

EDN: eosinophil-derived neurotoxin, SC: subcutaneous, IV: intravenous. * no established biomarker for this biologic agent.